The "Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 821 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Benefits

• Understand deal trends since 2016
• Browse precision medicine in oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

The report includes:

• Trends in precision medicine in oncology dealmaking in the biopharma industry
• Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
• The leading precision medicine in oncology deals by value
• Most active precision medicine in oncology licensing dealmakers

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

2.1. Introduction

2.2. Precision medicine in oncology deals over the years

2.3. Most active precision medicine in oncology dealmakers

2.4. Precision medicine in oncology deals by deal type

2.5. Precision medicine in oncology deals by therapy area

2.6. Precision medicine in oncology deals by industry sector

2.7. Deal terms for precision medicine in oncology deals

2.7.1 Precision medicine in oncology deals headline values

2.7.2 Precision medicine in oncology deal upfront payments

2.7.3 Precision medicine in oncology deal milestone payments

2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

3.1. Introduction

3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

4.1. Introduction

4.2. Most active precision medicine in oncology dealmakers

4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

5.1. Introduction

5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

Deal directory

• Deal directory - Precision medicine in oncology deals by company A-Z
• Deal directory - Precision medicine in oncology deals by deal type
• Deal directory - Precision medicine in oncology deals by therapy area
• Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/k3gplz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240703590178/en/